A Study of Genolair in Two Dosage Forms (Solution and Lyophilisate) and Xolair® in Healthy Volunteers

Prior treatment

• Use of drugs based on monoclonal antibodies (in routine practice for therapy and/or as part of a clinical trial) for ≤1 year before signing the informed consent AND/OR single use of drugs based on monoclonal antibodies (in routine practice for therapy and /or as part of a clinical trial) for ≤6 (six) half-lives of the drug before signing the informed consent.
• Use of drugs that affect the pharmacokinetics or pharmacodynamics of the study drugs (use of systemic corticosteroids for ≤30 days before signing the informed consent; use of systemic corticosteroids and monoclonal antibody preparations other than those being studied during the study period; use of immunosuppressive drugs, except for systemic corticosteroids, during the study period and/or use of these drugs for ≤30 days before signing the informed consent; vaccination (with any vaccine) within ≤30 days before signing the informed consent and/or the need for vaccination during the study period; initiation of allergen-specific immunotherapy within ≤3 months before signing the informed consent and/or need for its implementation during the study period).
• Acute infectious diseases less than 4 weeks before signing the informed consent.
• Donation of blood and its components or blood loss (450 ml of blood or more) less than 3 months before signing the informed consent.
• Participation in clinical trials of drugs less than 3 months before signing the informed consent.
• Regular alcohol consumption exceeding 5 units. alcohol per week (where each unit is equal to 30 ml of strong alcohol, 100 ml of wine or 250 ml of beer) or anamnestic information about alcoholism, drug addiction, drug abuse.
• Smoking more than 5 cigarettes per day for 3 months before signing the informed consent.
• Drug dependence and a positive urine test for the use of prohibited drugs and substances.
• Any planned surgical intervention during the study period.

Other illness

• History of use of drugs based on anti-IgE monoclonal antibodies.\*
• A history of an adverse drug reaction to any of the components of the study drug or comparator drugs.
• History of an autoimmune disease.
• The presence of chronic diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems, as well as diseases of the gastrointestinal tract, liver, kidneys, hematopoietic, immune systems, which, in the opinion of the Researcher, put the safety of the volunteer at risk when participating in the study, or which will impact on the analysis of safety data if an exacerbation of this disease occurs during the study period.
• A history of any cancer.
• History of mental illness.
• Deviations of vital signs: systolic pressure less than 100 mm Hg. Art. or more than 130 mm Hg. Art.; diastolic pressure less than 60 mm Hg. Art. or more than 90 mm Hg. Art.; heart rate less than 60 beats/min or more than 90 beats/min.
• Positive test results for hepatitis B and/or C, HIV, or syphilis.

Lab values

• A history of a disease associated with the accumulation of immune complexes (including serum sickness).

Other

• Special lifestyle (work at night, extreme physical activity).
• Positive test for the presence of alcohol in exhaled air.
• Unwillingness or inability to comply with the recommendations prescribed by this protocol.
• Reluctance to comply with contraceptive methods.

• Availability of written informed consent obtained from the volunteer prior to the start of any procedures related to the study;
• Men and women between the ages of 18 and 55 (inclusive) at the time of the Informed Consent Form including those diagnosed with atopic bronchial asthma (BA) and/or allergic rhinitis (AR) of mild severity according to the Investigator's conclusion;
• The absence of clinically significant changes in the volunteers according to the results of a physical examination, including measurement of blood pressure, heart rate, respiratory rate, body temperature, as well as laboratory tests, electrocardiography, and fluorography/chest X-ray;
• Bodyweight from 50 to 90 kg inclusive;
• Body mass index 18.5-30 kg / m2 inclusive;
• Initial concentration of total IgE: ≥30 IU / ml and ≤300 IU / m;
• The volume of forced exhalation in the first second (OFV1) ≥ 80% of the required value;
• Comply with the rules of contraception by the study participants.